Amphion Innovations plc
Update: Patent Litigation

London and New York, 29 August 2012– Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, announces that the United States District Court for the Southern District of New York issued its ruling concerning the construction of certain claim terms in the 402 and 502 patents.

DataTern is reviewing the ruling in these complex cases, conferring with counsel and considering all of its strategic options. DataTern continues to believe that these patents are valid and have been infringed.

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Cardew Group
Tim Robertson
+44 (0)20 7930 0777

Seymour Pierce Limited, Nominated Advisor
Mark Percy/Catherine Leftley
+44 (0)20 7107 8000


About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: